TY - JOUR A1 - Apsemidou, Athanasia A1 - Füller, Miriam Antonie A1 - Idelevich, Evgeny A. A1 - Kurzai, Oliver A1 - Tragiannidis, Athanasios A1 - Groll, Andreas H. T1 - Candida lusitaniae breakthrough fungemia in an immuno-compromised adolescent: case report and review of the literature JF - Journal of Fungi N2 - Candida lusitaniae is a rare cause of candidemia that is known for its unique capability to rapidly acquire resistance to amphotericin B. We report the case of an adolescent with grade IV graft-vs.-host disease after hematopoietic cell transplantation who developed catheter-associated C. lusitaniae candidemia while on therapeutic doses of liposomal amphotericin B. We review the epidemiology of C. lusitaniae bloodstream infections in adult and pediatric patients, the development of resistance, and its role in breakthrough candidemia. Appropriate species identification, in vitro susceptibility testing, and source control are pivotal to optimal management of C. lusitaniae candidemia. Initial antifungal therapy may consist of an echinocandin and be guided by in vitro susceptibility and clinical response. KW - Candida lusitaniae KW - candidemia KW - resistance KW - breakthrough KW - infection KW - transplantation Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-220125 SN - 2309-608X VL - 6 IS - 4 ER - TY - JOUR A1 - Sattler, Janko A1 - Noster, Janina A1 - Brunke, Anne A1 - Plum, Georg A1 - Wiegel, Pia A1 - Kurzai, Oliver A1 - Meis, Jacques F. A1 - Hamprecht, Axel T1 - Comparison of two commercially available qPCR kits for the detection of Candida auris JF - Journal of Fungi N2 - Candida auris is an emerging pathogen with resistance to many commonly used antifungal agents. Infections with C. auris require rapid and reliable detection methods to initiate successful medical treatment and contain hospital outbreaks. Conventional identification methods are prone to errors and can lead to misidentifications. PCR-based assays, in turn, can provide reliable results with low turnaround times. However, only limited data are available on the performance of commercially available assays for C. auris detection. In the present study, the two commercially available PCR assays AurisID (OLM, Newcastle Upon Tyne, UK) and Fungiplex Candida Auris RUO Real-Time PCR (Bruker, Bremen, Germany) were challenged with 29 C. auris isolates from all five clades and eight other Candida species as controls. AurisID reliably detected C. auris with a limit of detection (LoD) of 1 genome copies/reaction. However, false positive results were obtained with high DNA amounts of the closely related species C. haemulonii, C. duobushaemulonii and C. pseudohaemulonii. The Fungiplex Candida Auris RUO Real-Time PCR kit detected C. auris with an LoD of 9 copies/reaction. No false positive results were obtained with this assay. In addition, C. auris could also be detected in human blood samples spiked with pure fungal cultures by both kits. In summary, both kits could detect C. auris-DNA at low DNA concentrations but differed slightly in their limits of detection and specificity. KW - qPCR KW - detection limits KW - sensitivity KW - strain specificity KW - commercial kits KW - Candida auris KW - Fungiplex Candida Auris KW - AurisID Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228879 SN - 2309-608X VL - 7 IS - 2 ER - TY - JOUR A1 - Tappe, Beeke A1 - Lauruschkat, Chris D. A1 - Strobel, Lea A1 - Pantaleón García, Jezreel A1 - Kurzai, Oliver A1 - Rebhan, Silke A1 - Kraus, Sabrina A1 - Pfeuffer-Jovic, Elena A1 - Bussemer, Lydia A1 - Possler, Lotte A1 - Held, Matthias A1 - Hünniger, Kerstin A1 - Kniemeyer, Olaf A1 - Schäuble, Sascha A1 - Brakhage, Axel A. A1 - Panagiotou, Gianni A1 - White, P. Lewis A1 - Einsele, Hermann A1 - Löffler, Jürgen A1 - Wurster, Sebastian T1 - COVID-19 patients share common, corticosteroid-independent features of impaired host immunity to pathogenic molds JF - Frontiers in Immunology N2 - Patients suffering from coronavirus disease-2019 (COVID-19) are susceptible to deadly secondary fungal infections such as COVID-19-associated pulmonary aspergillosis and COVID-19-associated mucormycosis. Despite this clinical observation, direct experimental evidence for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-driven alterations of antifungal immunity is scarce. Using an ex-vivo whole blood stimulation assay, we challenged blood from twelve COVID-19 patients with Aspergillus fumigatus and Rhizopus arrhizus antigens and studied the expression of activation, maturation, and exhaustion markers, as well as cytokine secretion. Compared to healthy controls, T-helper cells from COVID-19 patients displayed increased expression levels of the exhaustion marker PD-1 and weakened A. fumigatus- and R. arrhizus-induced activation. While baseline secretion of proinflammatory cytokines was massively elevated, whole blood from COVID-19 patients elicited diminished release of T-cellular (e.g., IFN-γ, IL-2) and innate immune cell-derived (e.g., CXCL9, CXCL10) cytokines in response to A. fumigatus and R. arrhizus antigens. Additionally, samples from COVID-19 patients showed deficient granulocyte activation by mold antigens and reduced fungal killing capacity of neutrophils. These features of weakened anti-mold immune responses were largely decoupled from COVID-19 severity, the time elapsed since diagnosis of COVID-19, and recent corticosteroid uptake, suggesting that impaired anti-mold defense is a common denominator of the underlying SARS-CoV-2 infection. Taken together, these results expand our understanding of the immune predisposition to post-viral mold infections and could inform future studies of immunotherapeutic strategies to prevent and treat fungal superinfections in COVID-19 patients. KW - COVID-19 KW - immune impairment KW - T cells KW - granulocytes KW - Aspergillus KW - Rhizopus Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-283558 SN - 1664-3224 VL - 13 ER - TY - JOUR A1 - Springer, Jan A1 - Walther, Grit A1 - Rickerts, Volker A1 - Hamprecht, Axel A1 - Willinger, Birgit A1 - Teschner, Daniel A1 - Einsele, Hermann A1 - Kurzai, Oliver A1 - Loeffler, Juergen T1 - Detection of Fusarium Species in Clinical Specimens by Probe-Based Real-Time PCR JF - Journal of Fungi N2 - The mold Fusarium is a ubiquitous fungus causing plant, animal and human infections. In humans, Fusarium spp. are the major cause of eye infections in patients wearing contact lenses or after local trauma. Systemic infections by Fusarium spp. mainly occur in immunosuppressed patients and can disseminate throughout the human body. Due to high levels of resistance to antifungals a fast identification of the causative agent is an urgent need. By using a probe-based real-time PCR assay specific for the genus Fusarium we analysed several different clinical specimens detecting Fusarium spp. commonly found in clinical samples in Germany. Also, a large collection of lung fluid samples of haematological patients was analysed (n = 243). In these, two samples (0.8%) were reproducibly positive, but only one could be confirmed by sequencing. For this case of probable invasive fungal disease (IFD) culture was positive for Fusarium species. Here we describe a rapid, probe-based real-time PCR assay to specifically detect DNA from a broad range of Fusarium species and its application to clinically relevant specimens. KW - probe-based real-time PCR KW - Fusarium KW - bronchoalveolar lavage fluid KW - fungal molecular diagnostics Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193111 SN - 2309-608X VL - 5 IS - 4 ER - TY - JOUR A1 - Rohde, Jörn A1 - Himmel, Wolfgang A1 - Hofinger, Clemens A1 - Lâm, Thiên-Trí A1 - Schrader, Hanna A1 - Wallstabe, Julia A1 - Kurzai, Oliver A1 - Gágyor, Ildikó T1 - Diagnostic accuracy and feasibility of a rapid SARS-CoV-2 antigen test in general practice - a prospective multicenter validation and implementation study JF - BMC Primary Care N2 - Background PCR testing is considered the gold standard for SARS-CoV-2 diagnosis but its results are earliest available hours to days after testing. Rapid antigen tests represent a diagnostic tool enabling testing at the point of care. Rapid antigen tests have mostly been validated by the manufacturer or in controlled laboratory settings only. External validation at the point of care, particularly in general practice where the test is frequently used, is needed. Furthermore, it is unclear how well point of care tests are accepted by the practice staff. Methods In this prospective multicenter validation study in primary care, general practitioners included adult individuals presenting with symptoms suggesting COVID-19. Each patient was tested by the general practitioner, first with a nasopharyngeal swab for the point of care test (Roche SARS-CoV-2 Rapid Antigen Test) and then with a second swab for PCR testing. Using the RT-PCR result as a reference, we calculated specificity, sensitivity, positive predictive value and negative predictive value, with their 95% confidence intervals. General practitioners and medical assistants completed a survey to assess feasibility and usefulness of the point of care tests. Results In 40 practices in Würzburg, Germany, 1518 patients were recruited between 12/2020 and 06/2021. The point of care test achieved a sensitivity of 78.3% and a specificity of 99.5% compared to RT-PCR. With a prevalence of 9.5%, the positive predictive value was 93.9% and the negative predictive value was 97.8%. General practitioners rated the point of care test as a helpful tool to support diagnostics in patients with signs and symptoms suggestive for infection, particularly in situations where decision on further care is needed at short notice. Conclusion The point of care test used in this study showed a sensitivity below the manufacturer’s specification (Sensitivity 96.25%) in the practice but high values for specificity and high positive predictive value and negative predictive value. Although widely accepted in the practice, measures for further patient management require a sensitive interpretation of the point of care test results. KW - COVID-19 testing KW - feasibility study KW - attitude of health personnel KW - sensitivity and specificity KW - general practice Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-299659 VL - 23 IS - 1 ER - TY - JOUR A1 - Springer, Jan A1 - Held, Jürgen A1 - Mengoli, Carlo A1 - Schlegel, Paul Gerhardt A1 - Gamon, Florian A1 - Träger, Johannes A1 - Kurzai, Oliver A1 - Einsele, Hermann A1 - Loeffler, Juergen A1 - Eyrich, Matthias T1 - Diagnostic performance of (1→3)-β-D-glucan alone and in combination with aspergillus PCR and galactomannan in serum of pediatric patients after allogeneic hematopoietic stem cell transplantation JF - Journal of Fungi N2 - Data on biomarker-assisted diagnosis of invasive aspergillosis (IA) in pediatric patients is scarce. Therefore, we conducted a cohort study over two years including 404 serum specimens of 26 pediatric patients after allogeneic hematopoietic stem cell transplantation (alloSCT). Sera were tested prospectively twice weekly for Aspergillus-specific DNA, galactomannan (GM), and retrospectively for (1→3)-β-D-glucan (BDG). Three probable IA and two possible invasive fungal disease (IFD) cases were identified using the European Organization for Research and Treatment of Cancer and the Mycoses Study Group (EORTC/MSGERC) 2019 consensus definitions. Sensitivity and specificity for diagnosis of probable IA and possible IFD was 80% (95% confidential interval (CI): 28–99%) and 55% (95% CI: 32–77%) for BDG, 40% (95% CI: 5–85%) and 100% (95% CI: 83–100%) for GM, and 60% (95% CI: 15–95%) and 95% (95% CI: 75–100%) for Aspergillus-specific real-time PCR. However, sensitivities have to be interpreted with great caution due to the limited number of IA cases. Interestingly, the low specificity of BDG was largely caused by false-positive BDG results that clustered around the date of alloSCT. The following strategies were able to increase BDG specificity: two consecutive positive BDG tests for diagnosis (specificity 80% (95% CI: 56–94%)); using an optimized cutoff value of 306 pg/mL (specificity 90% (95% CI: 68–99%)) and testing BDG only after the acute posttransplant phase. In summary, BDG can help to diagnose IA in pediatric alloSCT recipients. However, due to the poor specificity either an increased cutoff value should be utilized or BDG results should be confirmed by an alternative Aspergillus assay. KW - beta-D-glucan KW - galactomannan KW - real-time PCR KW - Aspergillus KW - pediatric Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234179 SN - 2309-608X VL - 7 IS - 3 ER - TY - JOUR A1 - Aldejohann, Alexander Maximilian A1 - Wiese-Posselt, Miriam A1 - Gastmeier, Petra A1 - Kurzai, Oliver T1 - Expert recommendations for prevention and management of Candida auris transmission JF - Mycoses N2 - Candida auris was first described as a yeast pathogen in 2009. Since then, the species has emerged worldwide. In contrast to most other Candida spp., C. auris frequently exhibits multi-drug resistance and is readily transmitted in hospital settings. While most detections so far are from colonised patients, C. auris does cause superficial and life-threatening invasive infections. During management of the first documented C. auris transmission in a German hospital, experts from the National Reference Centers for Invasive Fungal Infections (NRZMyk) and the National Reference Center for Surveillance of Nosocomial Infections screened available literature and integrated available knowledge on infection prevention and C. auris epidemiology and biology to enable optimal containment. Relevant recommendations developed during this process are summarised in this guidance document, intended to assist in management of C. auris transmission and potential outbreak situations. Rapid and effective measures to contain C. auris spread require a multi-disciplinary approach that includes clinical specialists of the affected unit, nursing staff, hospital hygiene, diagnostic microbiology, cleaning staff, hospital management and experts in diagnostic mycology / fungal infections. Action should be initiated in a step-wise process and relevant interventions differ between management of singular C. auris colonised / infected patients and detection of potential C. auris transmission or nosocomial outbreaks. KW - Candida auris KW - nosocomial transmission KW - infection prevention KW - expert recommendation Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318570 VL - 65 IS - 6 SP - 590 EP - 598 ER - TY - JOUR A1 - Walther, Grit A1 - Zimmermann, Anna A1 - Theuersbacher, Johanna A1 - Kaerger, Kerstin A1 - Lilienfeld-Toal, Marie von A1 - Roth, Mathias A1 - Kampik, Daniel A1 - Geerling, Gerd A1 - Kurzai, Oliver T1 - Eye infections caused by filamentous fungi: spectrum and antifungal susceptibility of the prevailing agents in Germany JF - Journal of Fungi N2 - Fungal eye infections can lead to loss of vision and blindness. The disease is most prevalent in the tropics, although case numbers in moderate climates are increasing as well. This study aimed to determine the dominating filamentous fungi causing eye infections in Germany and their antifungal susceptibility profiles in order to improve treatment, including cases with unidentified pathogenic fungi. As such, we studied all filamentous fungi isolated from the eye or associated materials that were sent to the NRZMyk between 2014 and 2020. All strains were molecularly identified and antifungal susceptibility testing according to the EUCAST protocol was performed for common species. In total, 242 strains of 66 species were received. Fusarium was the dominating genus, followed by Aspergillus, Purpureocillium, Alternaria, and Scedosporium. The most prevalent species in eye samples were Fusarium petroliphilum, F. keratoplasticum, and F. solani of the Fusarium solani species complex. The spectrum of species comprises less susceptible taxa for amphotericin B, natamycin, and azoles, including voriconazole. Natamycin is effective for most species but not for Aspergillus flavus or Purpureocillium spp. Some strains of F. solani show MICs higher than 16 mg/L. Our data underline the importance of species identification for correct treatment. KW - eye infection KW - fungal infection KW - keratitis KW - antifungal susceptibility KW - natamycin KW - Fusarium KW - Purpureocillium KW - Aspergillus KW - Alternaria KW - Scedosporium Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-241810 SN - 2309-608X VL - 7 IS - 7 ER - TY - JOUR A1 - Zoran, Tamara A1 - Seelbinder, Bastian A1 - White, Philip Lewis A1 - Price, Jessica Sarah A1 - Kraus, Sabrina A1 - Kurzai, Oliver A1 - Linde, Joerg A1 - Häder, Antje A1 - Loeffler, Claudia A1 - Grigoleit, Goetz Ulrich A1 - Einsele, Hermann A1 - Panagiotou, Gianni A1 - Loeffler, Juergen A1 - Schäuble, Sascha T1 - Molecular profiling reveals characteristic and decisive signatures in patients after allogeneic stem cell transplantation suffering from invasive pulmonary aspergillosis JF - Journal of Fungi N2 - Despite available diagnostic tests and recent advances, diagnosis of pulmonary invasive aspergillosis (IPA) remains challenging. We performed a longitudinal case-control pilot study to identify host-specific, novel, and immune-relevant molecular candidates indicating IPA in patients post allogeneic stem cell transplantation (alloSCT). Supported by differential gene expression analysis of six relevant in vitro studies, we conducted RNA sequencing of three alloSCT patients categorized as probable IPA cases and their matched controls without Aspergillus infection (66 samples in total). We additionally performed immunoassay analysis for all patient samples to gain a multi-omics perspective. Profiling analysis suggested LGALS2, MMP1, IL-8, and caspase-3 as potential host molecular candidates indicating IPA in investigated alloSCT patients. MMP1, IL-8, and caspase-3 were evaluated further in alloSCT patients for their potential to differentiate possible IPA cases and patients suffering from COVID-19-associated pulmonary aspergillosis (CAPA) and appropriate control patients. Possible IPA cases showed differences in IL-8 and caspase-3 serum levels compared with matched controls. Furthermore, we observed significant differences in IL-8 and caspase-3 levels among CAPA patients compared with control patients. With our conceptual work, we demonstrate the potential value of considering the human immune response during Aspergillus infection to identify immune-relevant molecular candidates indicating IPA in alloSCT patients. These human host candidates together with already established fungal biomarkers might improve the accuracy of IPA diagnostic tools. KW - host response KW - invasive pulmonary aspergillosis KW - alloSCT patients KW - galectin-2 KW - caspase-3 KW - matrix metallopeptidase-1 Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262105 SN - 2309-608X VL - 8 IS - 2 ER - TY - THES A1 - Kurzai, Oliver T1 - Molekulare Charakterisierung pH-regulierter Gene bei der humanpathogenen Hefespezies Candida dubliniensis und ihr Nutzen für die epidemiologische Diagnostik T1 - PH-regulated genes of the pathogenic yeast Candida dubliniensis and their impact in epidemiological diagnostics N2 - Candida dubliniensis ist eine 1995 erstmals beschriebene pathogene Hefespezies mit enger phylogenetischer Verwandtschaft zu Candida albicans. Sie wird mittels routinemäßig angewendeter Verfahren nicht von C. albicans unterschieden, weil sie als einzige Spezies im Genus Candida neben C. albicans Chlamydosporen ausbilden kann. C. dubliniensis ist bisher vor allem aus dem Oropharynx HIV-positiver Patienten isoliert worden. PHR1 und PHR2 sind funktionell homologe, pH-abhängig exprimierte Gene von C. albicans, deren Produkte essentiell für die Verknüpfung von b-1,3- und b-1,6-Glukan in der Zellwand sind. Die Deletion jedes dieser Gene führt zu einem pH-abhängigen Phänotyp mit aberranter Morphogenese in vitro und reduzierter Virulenz im Tiermodell. In dieser Arbeit werden PHR homologe Gene im Genom von C. dubliniensis charakterisiert. CdPHR1 weist eine Homologie von 90,5 Prozent zu PHR1 und CdPHR2 eine Homologie von 91,7 Prozent zu PHR2 auf. Wie PHR1 wird auch CdPHR1 nur unter neutralen und alkalischen Bedingungen exprimiert, während sich CdPHR2 Transkript, wie das von PHR2, nur unter sauren Bedingungen nachweisen lässt. Die funktionelle Homologie von CdPHR1 zu PHR1 wird durch Komplementation des Phänotyps einer C. albicans phr1 Mutante mit CdPHR1 gezeigt. Dabei erweist sich der native Promoter von CdPHR1 als funktional in C. albicans. Im Modellorganismus Saccharomyces cerevisiae wird CdPHR1 unter Kontrolle seines nativen Promotors dagegen pH-unabhängig exprimiert. Auch die zusätzliche Einführung eines mutierten, dominant aktiven Allels von RIM101, das in C. albicans für die pH-abhängige Genexpression verantwortlich ist, hat darauf keinen Einfluss. In C. glabrata und Aspergillus nidulans findet sich keine Expression von CdPHR1. Basierend auf Sequenzunterschieden zwischen PHR1 und CdPHR1 wird ein PCR-Schnelltest zur Speziesunterscheidung entwickelt. Dieser wird in einer epidemiologischen Studie mit 133 chlamydosporenpositiven klinischen Isolaten evaluiert. 21 oropharyngeale Isolate von 14 HIV-positiven Patienten können so retrospektiv als C. dubliniensis klassifiziert werden, dies entspricht einer Prävalenz von C. dubliniensis in diesem Kollektiv von 30 Prozent. Die Ergebnisse der PCR werden durch Sequenzierung ribosomaler Gene (V3, ITS1, ITS2) bestätigt. Parallel werden phänotypische Tests zur Identifizierung von C. dubliniensis auf ihre diagnostische Validität getestet. Während sich die Chlamydosporenmorphologie der Isolate und die Koloniefärbung auf dem Farbindikatormedium CHROMagar Candida als unzulänglich für die Unterscheidung erweisen und das für C. dubliniensis beschriebene Wachstumsdefizit bei 45°C zwar sensitiv, nicht aber spezifisch für die Identifizierung dieser Spezies ist, korreliert die Koloniemorphologie auf Staib-Agar zu 100 Prozent mit den molekularen Daten. Alle C. dubliniensis Isolate werden in einem biochemischen Assay (Micronaut RC) untersucht, dabei zeigt der Test auf b-Glukosidase Aktivität hohes diskriminatorisches Potenzial. In Resistenztestungen zeigen sich die C. dubliniensis Isolate sensibler als die oropharyngealen C. albicans Isolate gegen gebräuchliche Antimykotika. In dieser Studie kann gezeigt werden, dass C. dubliniensis und C. albicans auf teilweise austauschbare Mechanismen zur Reaktion auf Alterationen des pH-Milieus verfügen. Die pH-abhängige Regulation zellwandassoziierter Gene ist dabei eng mit morphogenetischen Prozessen verbunden. Trotz dieser Ähnlichkeit ist C. dubliniensis nicht nur weniger virulent als C. albicans, sondern zeigt auch ein unterschiedliches epidemiologisches Spektrum, das durch eine Spezialisierung auf oropharyngeale Kolonisation und Infektion bei HIV-positiven Patienten gekennzeichnet ist. Um die Gründe für diese Unterschiede aufzeigen zu können, ist eine verlässliche Identifizierung von C. dubliniensis notwendig. Dazu stellen die präsentierten Daten einerseits einen schnellen und verlässlichen PCR Test, andererseits eine sorgfältige Evaluierung derzeit gebräuchlicher phänotypischer Verfahren vor. Phänotypisch und genotypisch exzellent charakterisierte Isolate beider Spezies stehen für weitere Untersuchungen zur Verfügung. N2 - Candida dubliniensis is a recently described pathogenic yeast species that is phylogenetically closely related to Candida albicans. In routine clinical diagnostic procedures both species are not differentiated due to the unique ability of C. dubliniensis to form germ-tubes and chlamydospores as C. albicans. Most C. dubliniensis isolates have been recovered from the oropharynx of HIV-infected patients. PHR1 and PHR2 are functionally homologous genes of C. albicans responsible for crosslinking b-1,3- and b-1,6-glucans of the yeast cell wall. These genes are characterized by a unique pattern of pH-dependent transcription. Deletion of each of these genes results in a pH-dependent phenotype with aberrant in vitro morphogenesis and reduced virulence in an animal model. Here, PHR homologous genes of C. dubliniensis are characterized. CdPHR1 is 90.5 per cent homologous to PHR1, CdPHR2 is 91.7 per cent homologous to PHR2. Like PHR1, CdPHR1 is only expressed in neutral to alkaline conditions, whereas CdPHR2 transcript - as with PHR2 - can only be found in acidic conditions. Functional homology of CdPHR1 with PHR1 is shown by complementation of a phr1 phenotype in C. albicans with CdPHR1. The native promoter of CdPHR1 is thereby shown to be functional in C. albicans. In contrast CdPHR1 is expressed in a pH-independent manner in bakers yeast Saccharomyces cerevisiae. This constitutive expression is not altered by additional integration of a dominant active allele of RIM101, encoding the transcription factor, that ensures pH-dependent gene expression in C. albicans. CdPHR1 is not expressed in C. glabrata and Aspergillus nidulans. A rapid PCR-test for discrimination between C. albicans and C. dubliniensis is constructed based on sequence differences between PHR1 and CdPHR1. This test is evaluated in an epidemiological study with 133 chlamydospore-positive clinical yeast isolates. 21 oropharyngeal isolates are retrospectively identified as C. dubliniensis, resulting in a prevalence of 30 per cent in this patient collective. PCR-results are confirmed by sequencing rDNA (V3, ITS1, ITS2). Phenotypic tests for identification of C. dubliniensis are evaluated with respect to their diagnostic potential. Whereas chlamydospore-morphology and colony colour on Chromagar Candida are not suited for reliable discrimination, and the growth deficit of C. dubliniensis at 45°C is sensitive but not specific, colony morphology on Staib agar corresponds 100 per cent to the molecular biology data. All C. dubliniensis isolates are biochemically characterized using the Micronaut RC system. The test for b-glucosidase activity within this system shows a high discriminatory potential. Susceptibility testing reveals, that the C. dubliniensis isolates are more sensitive to antifungals than the C. albicans isolates. C. dubliniensis and C. albicans rely on interchangeable mechanisms to react to the ambient pH. Furthermore, pH-regulated expression of cell wall associated genes is closely linked to morphogenesis. Despite this, C. dubliniensis is not only less virulent than C. albicans but also displays a distinct epidemiology characterized by a preference for oropharyngeal colonialization and infection of HIV-positive patients. To reveal the reasons for this, reliable identification of C. dubliniensis is necessary. For that purpose, a rapid PCR test is introduced together with an evaluation of currently available phenotypic methods. Thoroughly characterized isolates of both species are available for further studies. KW - Candida KW - albicans KW - dubliniensis KW - pH KW - PHR KW - CdPHR KW - RIM101 KW - Zellwand KW - Candida KW - albicans KW - dubliniensis KW - pH KW - PHR KW - CdPHR KW - RIM10 KW - cell wall Y1 - 2001 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-1182281 ER -